Sunday |
2:00 pm - 9:00 pm | Arrival and Check-in |
6:00 pm | Dinner |
7:30 pm - 7:40 pm | Welcome / Introductory Comments by GRC Site Staff |
7:40 pm - 9:30 pm | Keynote Session: Improving Drug Properties Through Mechanistic Modeling of Drug Disposition |
| Discussion Leader: Michael Zientek (Pfizer, USA) |
7:40 pm - 7:55 pm | Opening Remarks |
7:55 pm - 9:00 pm | Stephen Hall (Eli Lilly and Company, USA) "Improving Drug Properties Through Mechanistic Modeling of Drug Disposition" |
9:00 pm - 9:30 pm | Discussion |
Monday |
7:30 am - 8:30 am | Breakfast |
8:30 am | Group Photo |
9:00 am - 12:30 pm | PK Prediction: From Test Tube to Human |
| Discussion Leader: Karen Rowland-Yeo (SimCYP / Certara, USA) |
9:00 am - 9:05 am | Introduction by Discussion Leader |
9:05 am - 9:35 am | Christopher Gibson (Merck, USA) "IVIVE of UGT Data - Between Lot Variability in UGT Relative Activity Factor" |
9:35 am - 9:50 am | Discussion |
9:50 am - 10:20 am | Hannah Jones (Pfizer, USA) "Utility of PBPK Modelling and IVIVC Scaling Factors for the Prediction of Clinical PK for OATP Substrates" |
10:20 am - 10:35 am | Discussion |
10:35 am - 11:00 am | Coffee Break |
11:00 am - 11:30 am | Karen Rowland-Yeo (SimCYP / Certara, USA) "Application of PBPK Modeling in an Oncology Setting – Complex DDIs and Disease Interactions" |
11:30 am - 11:45 am | Discussion |
11:45 am - 12:15 pm | Steven Leeder (Children's Mercy Hospital, USA) "Pediatric PBPK Models: Shifting the Focus from Populations to Individuals" |
12:15 pm - 12:30 pm | Discussion |
12:30 pm | Lunch |
1:30 pm - 4:00 pm | Free Time |
4:00 pm - 6:00 pm | Poster Session |
6:00 pm | Dinner |
7:30 pm - 9:30 pm | Personalized Medicine: Pharmacogenomics and Disease States on Prediction of Drug Disposition |
| Discussion Leader: Erica Woodahl (University of Montana, USA) |
7:30 pm - 7:35 pm | Introduction by Discussion Leader |
7:35 pm - 8:05 pm | Steven Scherer (Human Genome Sequencing Center, USA) "Characterizing Difficult Drug Metabolism Gene Targets" |
8:05 pm - 8:15 pm | Discussion |
8:15 pm - 8:45 pm | Rachel Tyndale (University of Toronto, Canada) "Pharmacogenetic Variation in CYPs Alters Smoking, Tobacco-Related Diseases, and Smoking Treatment" |
8:45 pm - 8:55 pm | Discussion |
8:55 pm - 9:25 pm | Erica Woodahl (University of Montana, USA) "Pharmacogenomics with American Indian Populations: Unique Cytochrome P450 Variation" |
9:25 pm - 9:30 pm | Discussion |
Tuesday |
7:30 am - 8:30 am | Breakfast |
9:00 am - 12:30 pm | Oxidative Metabolism: The Advances and Challenges of In Silico, In Vitro and Prediction Sciences |
| Discussion Leader: Jane Kenny (Genentech, USA) |
9:00 am - 9:05 am | Introduction by Discussion Leader |
9:05 am - 9:35 am | Gabriele Cruciani (University of Perugia, Italy) "Predicting Metabolic Biotransformations, Fact or Fantasy?" |
9:35 am - 9:50 am | Discussion |
9:50 am - 10:20 am | Bill Smith (Gilead Sciences, USA) "Dealing with Those 'Other' Drug Metabolizing Enzymes: In Vitro and In Vivo Challenges" |
10:20 am - 10:35 am | Discussion |
10:35 am - 11:00 am | Coffee Break |
11:00 am - 11:30 am | Cyrus Khojasteh (Genentech, USA) "Understanding Mechanisms of Oxidation: Tools, Enzymes, and Electron Pushing" |
11:30 am - 11:45 am | Discussion |
11:45 am - 12:15 pm | Nina Isoherranen (University of Washington, USA) "Oxidative Metabolism During Pregnancy and in Infants: Maternal-Fetal Continuum in Drug and Vitamin Disposition" |
12:15 pm - 12:30 pm | Discussion |
12:30 pm | Lunch |
1:30 pm - 4:00 pm | Free Time |
4:00 pm - 6:00 pm | Poster Session |
6:00 pm | Dinner |
7:30 pm - 9:30 pm | Advances in Conjugative Metabolism: From Molecules to Populations |
| Discussion Leader: Michael Coughtrie (University of British Columbia, Canada) |
7:30 pm - 7:35 pm | Introduction by Discussion Leader |
7:35 pm - 8:05 pm | Chantal Guillemette (Laval University, Canada) "Splice Variants – Novel Regulators of UGT Function" |
8:05 pm - 8:15 pm | Discussion |
8:15 pm - 8:45 pm | Catherijne Knibbe (St. Antonius Hospital / LACDR, Leiden University, The Netherlands) "Predicting Drug Conjugation in Special Populations" |
8:45 pm - 8:55 pm | Discussion |
8:55 pm - 9:25 pm | Thomas Leyh (Albert Einstein College of Medicine, USA) "Human Sulfotransferases - What They Do, and How They Do It" |
9:25 pm - 9:30 pm | Discussion |
Wednesday |
7:30 am - 8:30 am | Breakfast |
9:00 am - 12:30 pm | Understanding and Predicting the Metabolism and Pharmacokinetics of Biologics |
| Discussion Leader: Dhavalkumar Shah (State University of New York at Buffalo, USA) |
9:00 am - 9:05 am | Introduction by Discussion Leader |
9:05 am - 9:35 am | E. Sally Ward (Texas A&M Health Science Center, USA) "Subcellular Trafficking and Metabolism of Biologics" |
9:35 am - 9:50 am | Discussion |
9:50 am - 10:20 am | Eric Ezan (Program Technologies for Health (PTTS), France) "Assessment of the Metabolism of Therapeutic Proteins and Antibodies" |
10:20 am - 10:35 am | Discussion |
10:35 am - 11:05 am | Coffee Break |
11:05 am - 11:35 am | Dhavalkumar Shah (State University of New York at Buffalo, USA) "Platform PBPK Model for Biologics and Its Evolution Towards Pediatric Population" |
11:35 am - 11:45 am | Discussion |
11:45 am - 12:15 pm | Honghui Zhou (Johnson & Johnson, USA) "Drug-Drug Interactions for Therapeutic Biologics" |
12:15 pm - 12:30 pm | Discussion |
12:30 pm | Lunch |
1:30 pm - 4:00 pm | Free Time |
4:00 pm - 6:00 pm | Poster Session |
6:00 pm | Dinner |
7:00 pm - 7:30 pm | Business Meeting |
| Nominations for the Next Vice Chair; Fill in Conference Evaluation Forms; Discuss Future Site and Scheduling Preferences; Election of the Next Vice Chair |
7:30 pm - 9:30 pm | Young Investigator Presentations |
| Discussion Leader: Henry Strobel (University of Texas Medical School at Houston, USA) |
7:30 pm - 7:40 pm | Introduction by Discussion Leader |
7:40 pm - 7:50 pm | Alenka Jaklic (University of Washington, USA) "Development of a Human Renal Proximal Tubule Microphysiological System for the Assessment of Drug Transport" |
7:50 pm - 7:55 pm | Discussion |
7:55 pm - 8:05 pm | Zoe Riches (University of British Columbia, Canada) "Pediatric Toxicity of Lamotrigine Through Inadequate Glucuronidation: An IVIVE and PBPK Modeling Approach to Rational Drug Dosing in Children" |
8:05 pm - 8:10 pm | Discussion |
8:10 pm - 8:20 pm | Sreeja Sarasamma (Rajiv Gandhi Centre for Biotechnology, India) "Impact of CYP3A5 Polymorphism on Tacrolimus to Predict the Optimal Initial Dose Requirements in South Indian Renal Transplant Recipients" |
8:20 pm - 8:25 pm | Discussion |
8:25 pm - 8:35 pm | Ryota Shizu (National Institute of Environmental Health Sciences, NIH, USA) "Inactive CAR Is a Homodimer that Dissociates for Activation" |
8:35 pm - 8:40 pm | Discussion |
8:40 pm - 8:50 pm | Isha Taneja (CSIR, Central Drug Research Institute (CDRI), India) "Metabolic Profiling, Metabolite Identification and CYP Inhibitory Potential of Medicarpin, a Potential Anti-Osteoporotic Agent, Using In Vitro Rat and Human Test Systems" |
8:50 pm - 8:55 pm | Discussion |
8:55 pm - 9:05 pm | Chunxue Wang (Vanderbilty University, USA) "Human Cytochrome P450 21A2 Crystal Structure and Phenotypes of Mutations" |
9:05 pm - 9:10 pm | Discussion |
9:10 pm - 9:30 pm | General Discussion |
Thursday |
7:30 am - 8:30 am | Breakfast |
9:00 am - 12:30 pm | Transporter Sciences: Evolving to a New Realm of Understanding Drug Interactions from a Victim Perspective |
| Discussion Leader: Caroline Lee (Ardea Biosciences, USA) |
9:00 am - 9:05 am | Introduction by Discussion Leader |
9:05 am - 9:35 am | Harma Ellens (GlaxoSmithKline Pharmaceuticals, USA) "Digoxin DDI and Appropriate In Vitro Models to Accommodate Uptake Kinetics" |
9:35 am - 9:50 am | Discussion |
9:50 am - 10:20 am | Katherine Fenner (AstraZeneca, United Kingdom) "Overlap in Drug-Drug Interactions Mediated via Influx, Efflux and Metabolism" |
10:20 am - 10:35 am | Discussion |
10:35 am - 11:00 am | Coffee Break |
11:00 am - 11:30 am | Mitchell Taub (Boehringer Ingelheim Pharmaceuticals, Inc., USA) "Probe Drug Cocktail for the Assessment of Transporter-Based Drug-Drug Interactions in a Clinical Setting" |
11:30 am - 11:45 am | Discussion |
11:45 am - 12:15 pm | Maciej Zamek-Gliszczynski (GlaxoSmithKline Pharmaceuticals, USA) "What Is the Optimal Metformin Clinical DDI Study Design that Enables a PD-Based Dose Adjustment Decision?" |
12:15 pm - 12:30 pm | Discussion |
12:30 pm | Lunch |
1:30 pm - 4:00 pm | Free Time |
4:00 pm - 6:00 pm | Poster Session |
6:00 pm | Dinner |
7:30 pm - 9:30 pm | Role of Proteomics and Mass Spectrometry in Drug Metabolism and Pharmacokinetic Prediction |
| Discussion Leader: Deepak Dalvie (Pfizer, USA) |
7:30 pm - 7:35 pm | Introduction by Discussion Leader |
7:35 pm - 8:05 pm | Philip Smith (University of North Carolina at Chapel Hill, USA) "Quantitating Drug Metabolizing Enzymes and Transporters by Using Stable Isotope-Labeled Peptide Standards and Liquid Chromatography-Tandem Mass Spectrometry" |
8:05 pm - 8:15 pm | Discussion |
8:15 pm - 8:45 pm | Stephen Castellino (GlaxoSmithKline Pharmaceuticals, USA) "MALDI Imaging MS: Snapshots of Drug Disposition in Tissues" |
8:45 pm - 8:55 pm | Discussion |
8:55 pm - 9:25 pm | Paul Hollenberg (University of Michigan, USA) "Mechanism-Based Inactivators of Cytochromes P450 as Probes of Structure and Function" |
9:25 pm - 9:30 pm | Discussion |
Friday |
7:30 am - 8:30 am | Breakfast |
9:00 am | Departure |